Content available at: https://www.ipinnovative.com/open-access-journals

Current Trends in Pharmacy and Pharmaceutical Chemistry

Journal homepage: https://www.ctppc.org/

Review Article

Review article on heterocyclic compounds with antimalarial activity

Arvind R Umarkar[1]*, Sandip B Sapkal[2], Hemantkumar J Dhongade[3], Mangesh Ajabrao Mapari[1]

[1]Dept. of Pharmaceutical Chemistry, Laddhad College of Pharmacy, Yelgaon Buldana, Maharashtra, India
[2]Dept. of Pharmaceutics, Laddhad College of Pharmacy, Yelgaon Buldana, Maharashtra, India
[3]Dept. of Pharmacognocy, Laddhad College of Pharmacy, Yelgaon Buldana, Maharashtra, India

Abstract

Malaria, caused by *Plasmodium* species, remains a major global health concern, particularly in tropical and subtropical regions. Despite the significant progress in malaria treatment, drug resistance has rendered many current therapies ineffective. As a result, the search for novel antimalarial compounds is crucial. Heterocyclic compounds, due to their structural diversity and bioactivity, have emerged as promising candidates for the development of new antimalarial agents. This review highlights the role of various heterocyclic compounds, including their chemical structures, mechanisms of action, and potential therapeutic applications in the treatment of malaria.

Keywords: Quinoline, Isoquinoline alkaloids, Imidazol, Pyrazolopyrimidine derivatives, Pyrazole derivatives.

Received: 03-01-2025; **Accepted:** 31-03-2025; **Available Online**: 05-05-2025

1. Introduction

Malaria is a life-threatening infectious disease caused by *Plasmodium* protozoa, transmitted primarily through the bites of infected Anopheles mosquitoes. The disease continues to cause millions of infections and deaths annually, predominantly in sub-Saharan Africa, Southeast Asia, and South America. Currently, malaria treatment relies on a few classes of drugs, including quinine derivatives, artemisinin-based combination therapies (ACTs), and other antimalarial agents. However, increasing resistance to these drugs has prompted the need for the development of new therapeutic agents.[1-4]

Heterocyclic compounds, which contain atoms such as nitrogen, oxygen, or sulfur in their ring structures, represent a diverse group of organic molecules that exhibit a wide range of biological activities, including antimalarial effects. This article reviews the most recent research on heterocyclic compounds with antimalarial properties, focusing on their chemical structures, modes of action, and potential for clinical development.

2. Overview of Heterocyclic Compounds

Heterocyclic compounds are organic compounds containing at least one atom (other than carbon) within the ring structure. These compounds have been widely studied due to their significant pharmacological properties. Depending on the heteroatom, they can be classified into several categories, including:

1. Nitrogen-containing heterocycles (e.g., pyrazoles, quinolines, imidazoles, and indoles)
2. Oxygen-containing heterocycles (e.g., benzofurans, isoflavones, and coumarins)
3. Sulfur-containing heterocycles (e.g., thiophenes and thiazoles)
4. Mixed heterocyclic compounds (e.g., thiazolopyridines, pyrazolopyrimidines)

*Corresponding author: Arvind R Umarkar
Email: arumankar@gmail.com

http://doi.org/ 10.18231/j.ctppc.2025.004

Each class exhibits distinct chemical properties that influence their interaction with biological systems, making them candidates for the treatment of malaria.

3. Mechanism of Action of Antimalarial Heterocyclic Compounds

The mechanism by which heterocyclic compounds exert antimalarial effects varies depending on their structure. Common mechanisms of action include:

3.1. Inhibition of hemoglobin digestion

The *Plasmodium* parasite, upon infecting red blood cells, digests host hemoglobin to obtain amino acids necessary for its growth. During this process, toxic heme is released, which must be detoxified to prevent damage to the parasite. Compounds like quinolines (e.g., chloroquine and mefloquine) and quinazoline derivatives interfere with this detoxification process, leading to the accumulation of toxic heme and parasite death.[5,6]

3.2. Inhibition of folic acid metabolism

Folic acid is essential for DNA synthesis in both the parasite and the host. Several heterocyclic compounds, such as pyrimidines and purines, inhibit the folate biosynthesis pathway in *Plasmodium*, thereby preventing the parasite's replication. For example, pyrimethamine targets the enzyme dihydrofolate reductase, a critical enzyme in folic acid metabolism.

3.3. Disruption of protein synthesis

Heterocyclic compounds such as imidazoles and benzimidazoles have been shown to interfere with the protein synthesis machinery of the parasite, specifically targeting ribosomal RNA or enzymes involved in translation.

3.4. Interaction with the mitochondrial electron transport chain

Some heterocyclic compounds, including thiazoles and quinolines, disrupt the mitochondrial electron transport chain in *Plasmodium*. This interference leads to a decrease in ATP production, thereby inhibiting the parasite's ability to carry out essential metabolic processes.

3.5. Modulation of host immune response

Certain heterocyclic compounds have also been reported to modulate the host's immune system, enhancing the body's ability to fight off the infection. These compounds may stimulate the production of cytokines or activate immune cells such as macrophages and T lymphocytes.

4. Promising Heterocyclic Compounds with Antimalarial Activity

Several heterocyclic compounds have shown promising antimalarial activity in vitro and in vivo. Below are some noteworthy examples:

4.1. Quinoline derivatives

Quinoline derivatives are a class of heterocyclic compounds that contain a bicyclic structure consisting of a benzene ring fused to a pyridine ring. The basic quinoline structure consists of a nitrogen atom in the six-membered ring, which plays a crucial role in the compound's pharmacological properties.[7]

Quinoline Derivatives can be classified into several subclasses based on structural modifications, including:

1. Chloroquine and Hydroxychloroquine: The first synthetic quinolines widely used for malaria treatment.
2. Mefloquine: A second-line drug for the treatment of resistant malaria.
3. Primaquine: Used for the radical cure of *Plasmodium vivax* and *Plasmodium ovale* malaria.
4. Quinoline Methanols: Include drugs like tafenoquine, which has shown promise in treating relapse forms of malaria.

Chemical modifications at various positions on the quinoline ring, such as the introduction of different side chains, halogen substitutions, or changes to the N-heterocyclic ring, can significantly impact the drug's potency, pharmacokinetics, and the ability to overcome resistance.

4.1.1. Mechanism of Action of Quinoline Derivatives

The antimalarial action of quinoline derivatives primarily involves their ability to interfere with the parasite's metabolism, especially during its asexual erythrocytic stage. The mechanisms include:

4.1.1.1. Inhibition of hemoglobin digestion and heme detoxification

One of the key targets of quinoline derivatives is the parasite's ability to digest host hemoglobin. Infected erythrocytes provide the *Plasmodium* parasite with a large supply of hemoglobin, which it breaks down into peptides. During this process, toxic heme is released. Normally, the parasite detoxifies heme into a non-toxic form by polymerizing it into hemozoin. Quinoline derivatives inhibit the polymerization of heme, leading to the accumulation of toxic free heme, which damages the parasite's cellular structures and ultimately causes its death.[8]

1. Chloroquine and Hydroxychloroquine: These drugs accumulate in the acidic food vacuole of the parasite, where they bind to free heme, preventing its polymerization and thereby generating toxic levels of free heme.

4.1.1.2. Inhibition of folate pathway

Some quinoline derivatives, like pyrimethamine, which is structurally similar to quinoline, inhibit the enzyme dihydrofolate reductase (DHFR) in the folate biosynthesis pathway. This enzyme is essential for the parasite's ability to synthesize nucleic acids. While pyrimethamine is not a typical quinoline, this mechanism highlights the importance of folate metabolism in *Plasmodium* survival and provides a point of intervention for quinoline-related compounds.

4.1.1.3. Interference with mitochondrial function

Recent studies have shown that some quinoline derivatives, such as mefloquine and quinine, may also exert antimalarial effects by interfering with mitochondrial function in the parasite. Mefloquine, for example, has been suggested to disrupt the parasite's mitochondrial electron transport chain, leading to a reduction in ATP production and subsequent cell death.[9]

4.1.1.4. Inhibition of protein synthesis

Certain quinoline derivatives may also affect the parasite's ability to synthesize proteins necessary for its replication. For instance, mefloquine has been proposed to inhibit ribosomal RNA translation or interfere with specific translation factors.

4.1.2. Challenges and limitations

4.1.2.1. Drug resistance

The rise of drug-resistant malaria, particularly in Southeast Asia, poses a significant challenge to the effectiveness of quinoline derivatives. The resistance mechanisms, such as mutations in the PfCRT, PfMDR1, and other transporters, reduce the accumulation of quinoline drugs in the parasite, rendering them ineffective. This has led to the development of combination therapies to prevent the development of resistance.[10]

4.1.2.2. Toxicity

While quinoline derivatives are generally well-tolerated, they can cause side effects, particularly with prolonged use. These include gastrointestinal symptoms, skin rashes, and, in the case of mefloquine, neuropsychiatric effects such as anxiety, depression, and vivid dreams. Monitoring is essential, especially when used in travelers or patients with pre-existing conditions.

4.1.2.3. Global supply and access

Access to quinoline-based drugs can be limited in low-resource settings, where the burden of malaria is highest. Cost, supply chain disruptions, and insufficient healthcare infrastructure contribute to challenges in providing adequate treatment.

4.2. Isoquinoline alkaloids

4.2.1. Chemical structure of isoquinoline alkaloids

Isoquinoline alkaloids are characterized by an isoquinoline skeleton, consisting of a benzene ring fused to a nitrogen-containing heterocyclic ring. Their structures can be modified with different functional groups, including methyl, hydroxyl, methoxy, and amino groups, which can influence their pharmacological properties.

Key isoquinoline alkaloids with antimalarial activity include:

1. Quinine**:** A well-known alkaloid obtained from the bark of the cinchona tree (*Cinchona officinalis*), quinine has been used for centuries to treat malaria. Its structure features a bicyclic isoquinoline system with a quinoline nucleus attached to a side chain.
2. Berberine**:** Found in several plants, including *Berberis* species, berberine is a naturally occurring isoquinoline alkaloid with a broad range of biological activities, including antimicrobial, anti-inflammatory, and antimalarial effects.
3. Tetrahydroberberine**:** A reduced form of berberine, tetrahydroberberine has shown promising antimalarial activity and is being studied for its potential in treating multidrug-resistant malaria.
4. Laudanosine: Found in the opium poppy (*Papaver somniferum*), laudanosine is another isoquinoline alkaloid with notable antimalarial activity.

The presence of various functional groups, including quinuclidine, isoquinoline, and methoxy groups, in these compounds plays an essential role in their interaction with biological targets and contributes to their antimalarial efficacy.

4.2.2. Mechanism of action of isoquinoline alkaloids

4.2.2.1. Inhibition of heme detoxification

Similar to other antimalarial agents, isoquinoline alkaloids are believed to target the parasite's ability to digest and detoxify heme, a byproduct of hemoglobin breakdown. During the asexual erythrocytic stage, the parasite ingests host red blood cells and digests hemoglobin, releasing free heme, which is toxic to the parasite. The parasite typically converts free heme into a nontoxic polymer, hemozoin, within a specialized vacuole.[11,12]

Quinine and related isoquinoline alkaloids inhibit this polymerization process by binding to the free heme in the parasite's digestive vacuole, preventing its polymerization into hemozoin. This accumulation of free heme damages the parasite's cellular structures and leads to its death.

4.2.2.2. Disruption of membrane potential and energy production

Isoquinoline alkaloids, particularly quinine and quinidine, have been shown to interfere with the parasite's

mitochondrial function. These compounds disrupt the mitochondrial membrane potential and ATP production, which are critical for the parasite's survival. This mitochondrial disruption affects key cellular processes such as protein synthesis, transport, and energy production.

In addition, quinine has been found to inhibit the parasite's ATPase activity, which is essential for maintaining cellular functions and ionic balance. This further compromises the parasite's ability to survive within the host.

4.2.2.3. Inhibition of parasite metabolism

Isoquinoline alkaloids may also interfere with *Plasmodium* metabolism in other ways, such as inhibiting enzymes involved in the folate metabolism pathway. For example, berberine has been shown to inhibit enzymes involved in the biosynthesis of nucleic acids and other essential metabolites within the parasite, leading to metabolic dysfunction and parasite death.

4.2.2.4. Interaction with host immune response

Some isoquinoline alkaloids, including berberine, may modulate the host's immune response to the parasite. Berberine has demonstrated anti-inflammatory effects, which may help alleviate the immune system's overreaction during malaria infection, while also reducing parasite load. This immune modulation may have a synergistic effect when combined with other antimalarial agents.

4.3. Pyrazole and pyrazolopyrimidine derivatives

4.3.1. Pyrazole derivatives

Pyrazole is a five-membered aromatic heterocycle containing two adjacent nitrogen atoms in positions 1 and 2. Substituted pyrazoles can be synthesized by various methods, and the introduction of different functional groups at positions 3 and 5 of the pyrazole ring significantly alters the compound's pharmacological properties.

Common substitutions include:

1. Aryl groups at positions 3 and 5 of the pyrazole ring, such as phenyl, methyl, and halogen substituents.
2. Alkyl groups to improve solubility and pharmacokinetics.
3. Amino and hydroxy groups, which may enhance the compound's interaction with biological targets.

Examples of pyrazole derivatives studied for antimalarial activity include 3,5-disubstituted pyrazoles, 1,2,4-triazole-pyrazole hybrids, and pyrazole-based thiol inhibitors.

4.3.2. Pyrazolopyrimidine derivatives

Pyrazolopyrimidines are fused heterocyclic compounds containing a pyrazole ring attached to a pyrimidine ring. These compounds combine the properties of both pyrazole and pyrimidine, making them versatile for interacting with a wide range of biological targets. The structural diversity of pyrazolopyrimidines, achieved through modifications to the pyrazole and pyrimidine moieties, further increases their potential for antimalarial activity.[13]

Pyrazolopyrimidines are often synthesized by cyclization reactions that link a pyrazole ring to a pyrimidine or other nitrogen-containing heterocyclic ring. Substitutions at various positions of the pyrimidine or pyrazole ring can fine-tune their biological activity.

4.3.3. Mechanisms of action of pyrazole and pyrazolopyrimidine derivatives

4.3.3.1. Inhibition of folate pathway

One of the most common mechanisms of action of pyrazole and pyrazolopyrimidine derivatives involves inhibition of the folate biosynthesis pathway, which is essential for the production of nucleic acids and cellular components in *Plasmodium*. Folate metabolism is crucial for the parasite's ability to synthesize purines and pyrimidines, and disrupting this pathway can severely hinder its growth and replication.

Several pyrazolopyrimidine derivatives, including compounds like pyrazolopyrimidines and pyrazolyl-triazole hybrids, have been found to act as potent inhibitors of dihydrofolate reductase (DHFR), a key enzyme in folate metabolism. DHFR inhibitors prevent the conversion of dihydrofolate to tetrahydrofolate, which is necessary for the synthesis of nucleic acids and the parasite's survival.[14]

4.3.3.2. Inhibition of heme detoxification

Similar to other antimalarial drugs, some pyrazole derivatives may interfere with the *Plasmodium* parasite's ability to detoxify heme, a byproduct of hemoglobin degradation. Infected erythrocytes provide the parasite with abundant hemoglobin, which it breaks down into toxic free heme. Normally, the parasite polymerizes free heme into nontoxic hemozoin. Pyrazole derivatives can inhibit this process, leading to the accumulation of toxic free heme, which disrupts the parasite's cellular processes and causes cell death.

Some pyrazolopyrimidines have been reported to bind directly to heme or interfere with the enzymes responsible for heme detoxification, thus amplifying the cytotoxic effects of free heme.

4.3.3.3. Targeting plasmodial enzymes

Pyrazole and pyrazolopyrimidine derivatives may also inhibit specific *Plasmodium* enzymes that are crucial for the parasite's survival. For instance, compounds targeting *Plasmodium* proteases or kinases can disrupt the parasite's protein synthesis and cellular regulation. Enzymes such as protein kinase G (PKG), an essential enzyme for regulating

Plasmodium motility and invasion of host cells, are potential targets for pyrazole and pyrazolopyrimidine derivatives.[15]

4.3.3.4. Membrane disruption and mitochondrial targeting

Some pyrazole-based compounds may also disrupt the parasite's mitochondrial functions. The mitochondrial membrane potential is vital for energy production in the parasite, and disruption can lead to ATP depletion and parasite death. These compounds may act on mitochondrial proteins, affecting the parasite's ability to generate energy, leading to a halt in its replication.[16]

4.3.4. Antimalarial activity of pyrazole and pyrazolopyrimidine derivatives

4.3.4.1. Pyrazole derivatives

Pyrazole derivatives have shown promising in vitro and in vivo activity against *Plasmodium falciparum*, the most lethal species responsible for malaria. Some of the most effective pyrazole derivatives have been designed as inhibitors of key enzymes, such as DHFR or proteases, involved in parasite metabolism.

For example, compounds like 3,5-disubstituted pyrazoles have exhibited potent antimalarial activity by inhibiting the enzyme DHFR and other folate pathway enzymes. These compounds can reduce the parasite load in infected individuals and show low cytotoxicity to host cells, making them potential candidates for drug development.

Pyrazole derivatives have also demonstrated a wide range of interactions with other targets, such as *Plasmodium* kinases and proteases, making them attractive candidates for drug development.

4.3.4.2. Pyrazolopyrimidine derivatives

Pyrazolopyrimidines have been extensively studied for their antimalarial potential due to their ability to inhibit key enzymes in the folate metabolism pathway. For instance, pyrazolopyrimidine-based DHFR inhibitors have been shown to effectively block the folate biosynthesis pathway in *Plasmodium falciparum*, leading to a reduction in parasitemia.

In addition, pyrazolopyrimidine-thiazole hybrids have demonstrated antimalarial activity by targeting multiple stages of the parasite lifecycle. These compounds act by inhibiting both the schizont stage (which is responsible for the clinical manifestations of malaria) and the gametocyte stage, which is essential for transmission to mosquitoes.

Moreover, some pyrazolopyrimidines have shown enhanced bioavailability and metabolic stability, making them potential candidates for further development as therapeutic agents.

4.3.5. Challenges and limitations

4.3.5.1. Drug resistance

The emergence of resistance to conventional antimalarial drugs is a major challenge in the development of new therapies. While pyrazole and pyrazolopyrimidine derivatives have shown promise, resistance to certain classes of these compounds may also develop. Continuous monitoring and the use of combination therapies will be necessary to combat resistance.

4.3.5.2. Toxicity and side effects

As with any drug development process, toxicity remains a concern. Some pyrazole derivatives, particularly those targeting mitochondrial function, can cause off-target effects that may lead to toxicity in host cells. Pyrazolopyrimidine derivatives that inhibit DHFR may also cause side effects such as gastrointestinal distress or liver toxicity. Therefore, careful optimization of these compounds is necessary to reduce side effects while maintaining efficacy.

4.3.5.3. Pharmacokinetics

The bioavailability and pharmacokinetic profiles of pyrazole and pyrazolopyrimidine derivatives vary. Some compounds may have poor solubility or bioavailability, limiting their potential as oral antimalarial drugs. Strategies such as prodrug development, nanoparticle-based delivery systems, and formulation enhancements can improve the pharmacokinetics of these compounds.

4.4. Imidazole derivatives

Imidazole is a heterocyclic compound with the chemical formula $C_3H_4N_2$. The core imidazole ring consists of a five-membered structure containing two nitrogen atoms at positions 1 and 3. Substituting different functional groups at various positions on the imidazole ring can significantly alter the compound's biological activity.

Common substitutions include:

1. Aryl groups: Phenyl or substituted phenyl groups at positions 2, 4, or 5, which can enhance lipophilicity and interaction with *Plasmodium* enzymes.
2. Alkyl groups: These can increase solubility and bioavailability.
3. Halogen atoms: Such as chlorine or fluorine, which can alter the pharmacokinetic properties and potentially reduce toxicity.
4. Hydroxyl, amino, or methoxy groups: These substitutions can enhance antimalarial activity by improving binding affinity to biological targets.

Imidazole derivatives are often synthesized by modifying the imidazole ring through various chemical processes, including nucleophilic substitution, cyclization, and functional group addition.

4.4.1. Mechanisms of action of imidazole derivatives

Imidazole derivatives have demonstrated antimalarial activity through several mechanisms, acting on different stages of the *Plasmodium* lifecycle. Some of the major mechanisms include:

4.4.1.1. Inhibition of heme detoxification

Like other antimalarial agents, many imidazole derivatives target the parasite's ability to detoxify heme, a byproduct of hemoglobin breakdown during the erythrocytic stage. In the digestive vacuole of the parasite, free heme is released from hemoglobin and is normally polymerized into hemozoin by the parasite to prevent its toxicity. Imidazole derivatives can interfere with this polymerization process, leading to the accumulation of toxic free heme, which disrupts parasite cellular processes and leads to cell death.

Some imidazole derivatives have been shown to bind to heme directly or inhibit the heme polymerase enzyme, thereby preventing the conversion of heme to hemozoin. This mechanism is similar to that of well-known antimalarial drugs such as chloroquine and quinine.

4.4.1.2. Inhibition of plasmodial enzymes

Many imidazole derivatives act by inhibiting specific enzymes essential for the survival of *Plasmodium* parasites. For example:

1. Dihydrofolate reductase (DHFR): Some imidazole derivatives act as inhibitors of DHFR, a key enzyme involved in the folate metabolism pathway. DHFR catalyzes the reduction of dihydrofolate to tetrahydrofolate, which is required for the synthesis of nucleotides. Inhibition of this enzyme disrupts nucleic acid synthesis and impairs parasite growth.
2. Plasmodial proteases: Imidazole derivatives may also inhibit *Plasmodium* proteases, enzymes involved in processing and degradation of host proteins that the parasite uses for growth. This can disrupt the parasite's ability to metabolize host proteins and reproduce.

4.4.1.3. Disruption of membrane integrity

Some imidazole derivatives have been found to interact with the plasma membrane of *Plasmodium* parasites, disrupting the integrity of the cell membrane and causing leakage of essential cellular contents. This can lead to the collapse of the parasite's metabolic processes and its eventual death.

4.4.1.4. Inhibition of mitochondrial function

Imidazole derivatives, like many other antimalarial agents, can target the mitochondria of *Plasmodium*. Mitochondria play a crucial role in energy production and cellular regulation in the parasite. Disruption of mitochondrial function can impair ATP production, essential for the parasite's survival. This may involve inhibition of mitochondrial enzymes or the induction of mitochondrial membrane depolarization.

4.4.1.5. Thiazole and thiazolopyridine derivatives

Thiazole derivatives have shown promising results by targeting the electron transport chain in the mitochondria of the parasite. Thiazolopyridines, in particular, exhibit activity against *Plasmodium falciparum*, and their potential for development into clinical antimalarial drugs is under investigation.

5. Challenges and Future Directions

While heterocyclic compounds exhibit significant potential in malaria therapy, several challenges remain, including:

1. Development of drug resistanc**e**: As with any antimalarial drug, the rapid emergence of resistance remains a critical challenge. Strategies to circumvent resistance include developing combination therapies and modifying the chemical structures of existing compounds.
2. Toxicity and side effects: Some heterocyclic compounds can exhibit toxicity, particularly in long-term use. Further research is needed to balance efficacy with safety profiles.
3. Bioavailability: Many heterocyclic compounds face issues with absorption, metabolism, and distribution within the human body, which may limit their clinical application. Prodrugs or novel delivery systems could address this limitation.

Despite these challenges, the continued exploration of heterocyclic compounds remains a promising avenue for developing next-generation antimalarial agents.

6. Discussion

Heterocyclic compounds have long been a cornerstone in medicinal chemistry due to their versatility in interacting with biological targets. This makes them valuable candidates for the development of antimalarial drugs. Malaria, caused by Plasmodium species, particularly Plasmodium falciparum, remains one of the leading causes of morbidity and mortality in tropical and subtropical regions. The emergence of drug resistance, especially to first-line antimalarials like chloroquine and artemisinin, has created an urgent need for novel therapeutic agents. Heterocyclic compounds, owing to their structural diversity and pharmacological versatility, offer a promising strategy to address this need.[14,15,16]

7. Conclusion

Heterocyclic compounds offer a rich source of novel antimalarial agents, with various classes showing promising activity against *Plasmodium* species. Their diverse mechanisms of action, including inhibition of heme detoxification, folic acid metabolism, and protein synthesis,

make them attractive candidates for therapeutic development. Ongoing research into the synthesis, optimization, and clinical evaluation of these compounds will likely play a significant role in combating malaria, especially in the face of increasing drug resistance.

8. Source of Funding

None.

9. Conflict of Interest

None.

References

1. Wicht KJ, Mok S, Fidock DA. Molecular Mechanisms of Drug Resistance in Plasmodium falciparum Malaria. *Annu Rev Microbiol*. 2020:74:431–54.
2. Vangapandu S, Jain M, Kaur K, Patil P, Patel SR, Jain R. Recent advances in antimalarial drug development. *Med Res Rev*. 2007;27(1):65–107.
3. Kumar S, Singh RK, Patial B, Goyal S, Bhardwaj TR. Recent advances in novel heterocyclic scaffolds for the treatment of drug-resistant malaria. *J Enzyme Inhib Med Chem*. 2016;31(2):173–86.
4. Klingenstein R, Melnyk P, Leliveld SR, Ryckebusch A, Korth C. Similar Structure−Activity relationships of quinoline derivatives for antiprion and antimalarial effects. *J Med Chem*. 2006;49(17):5300–8.
5. Coetzee J, Cronje S, Dobrzańska L, Raubenheimer HG, Jooné G, Nell MJ, et al. Novel N-heterocyclic ylideneamine gold(i) complexes: synthesis, characterisation and screening for antitumour and antimalarial activity. *Dalton Transactions*. 2011;40(7):1471.
6. Iwasa K, Moriyasu M, Tachibana Y, Kim HS, Wataya Y, Wiegrebe W, et al. Simple isoquinoline and benzylisoquinoline alkaloids as potential antimicrobial, antimalarial, cytotoxic, and Anti-HIV agents. *Bioorganic Med Chem*. 2001;9(11):2871–84.
7. Deng X, Nagle A, Wu T, Sakata T, Henson K, Chen Z, et al. Discovery of novel 1H-imidazol-2-yl-pyrimidine-4,6-diamines as potential antimalarials. *Bioorganic Med Chem Lett*. 2010;20(14):4027–31.
8. Kannan M, Raichurkar AV, Khan FRN, Iyer PS. Synthesis and in vitro evaluation of novel 8-aminoquinoline–pyrazolopyrimidine hybrids as potent antimalarial agents. *Bioorganic Med Chem Lett*.2015 Jan 9;25(5):1100–3.
9. Kumar G, Tanwar O, Kumar J, Akhter M, Sharma S, Pillai CR, et al. Pyrazole-pyrazoline as promising novel antimalarial agents: A mechanistic study. *Eur J Med Chem*. 2018 Feb 15;149:139–47.
10. Jomaa H, Wiesner J, Sanderbrand S, Altincicek B, Weidemeyer C, Hintz M, et al. Inhibitors of the nonmevalonate pathway of isoprenoid biosynthesis as antimalarial drugs. *Science*. 1999 Sep 3;285(5433):1573–6.
11. Ramakrishna KKG, Gunjan S, Shukla AK, Pasam VR, Balaramnavar VM, Sharma A, et al. Identification of Novel Phenyl Butenonyl C-Glycosides with Ureidyl and Sulfonamidyl Moieties as Antimalarial Agents. *ACS Med Chem Lett*. 2014;5(8):878–83.
12. Sanz LM, Crespo B, De-Cózar C, Ding XC, Llergo JL, Burrows JN, et al. P. falciparum In Vitro Killing Rates Allow to Discriminate between Different Antimalarial Mode-of-Action. *PLoS One*. 2012;7(2):e30949.
13. Ullah I, Sharma R, Mete A, Biagini GA, Wetzel DM, Horrocks PD. The relative rate of kill of the MMV Malaria Box compounds provides links to the mode of antimalarial action and highlights scaffolds of medicinal chemistry interest. *J Antimicrob Chemother*. 2019;75(2):362–70.
14. Yadav S, Singh S, Gupta C. A concise overview on heterocyclic compounds exhibiting pesticidal activities. *Int J Adv Res*. 2021;9(08):989–1004.
15. Li R, Kenyon GL, Cohen FE, Chen X, Gong B, Dominguez JN, et al. In vitro antimalarial activity of chalcones and their derivatives. *J Med Chem*. 1995;38(26):5031–7.
16. Márquez IG, Akuaku J, Cruz I, Cheetham J, Golshani A, Smith ML. Disruption of protein synthesis as antifungal mode of action by chitosan. *Int J Food Microbiol*. 2013;164(1):108–12.

Cite this article Umarkar AR, Sapkal SB, Dhongade HJ, Mapari MA. Review article on heterocyclic compounds with antimalarial activity. *Curr Trends Pharm Pharm Chem*. 2025;7(1):20-26.